Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
vamotinib (PF-114)
i
Other names:
PF-114, PF 114
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
AstraZeneca
Drug class:
Bcr-abl tyrosine kinase inhibitor
Related drugs:
‹
dasatinib (215)
imatinib (166)
nilotinib (66)
bosutinib (46)
asciminib (14)
olverembatinib (12)
flumatinib (5)
INNO-406 (3)
TGRX-678 (2)
KF-1601 (1)
SCO - 088 (1)
AZD 0424 (0)
dasatinib amorphous (0)
ELVN-001 (0)
KW-2449 (0)
radotinib (0)
TERN-701 (0)
XL228 (0)
PHA-739358 (0)
AER-901 (0)
SKLB-1028 (0)
dasatinib (215)
imatinib (166)
nilotinib (66)
bosutinib (46)
asciminib (14)
olverembatinib (12)
flumatinib (5)
INNO-406 (3)
TGRX-678 (2)
KF-1601 (1)
SCO - 088 (1)
AZD 0424 (0)
dasatinib amorphous (0)
ELVN-001 (0)
KW-2449 (0)
radotinib (0)
TERN-701 (0)
XL228 (0)
PHA-739358 (0)
AER-901 (0)
SKLB-1028 (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
PF-114
Sensitive: C3 – Early Trials
PF-114
Sensitive
:
C3
PF-114
Sensitive: C3 – Early Trials
PF-114
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login